155 related articles for article (PubMed ID: 37649596)
41. Sea-urchin-like Au nanocluster with surface-enhanced raman scattering in detecting epidermal growth factor receptor (EGFR) mutation status of malignant pleural effusion.
Wang L; Guo T; Lu Q; Yan X; Zhong D; Zhang Z; Ni Y; Han Y; Cui D; Li X; Huang L
ACS Appl Mater Interfaces; 2015 Jan; 7(1):359-69. PubMed ID: 25495142
[TBL] [Abstract][Full Text] [Related]
42. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.
Schwalk AJ; Ost DE; Saltijeral SN; De La Garza H; Casal RF; Jimenez CA; Eapen GA; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee J; Elamin Y; Zhang J; Roth JA; Swisher S; Heymach JV; Grosu HB
Chest; 2021 Mar; 159(3):1256-1264. PubMed ID: 33217413
[TBL] [Abstract][Full Text] [Related]
43. Pleural involvement in lung cancer.
Agalioti T; Giannou AD; Stathopoulos GT
J Thorac Dis; 2015 Jun; 7(6):1021-30. PubMed ID: 26150915
[TBL] [Abstract][Full Text] [Related]
44. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
45. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
46. Myocardin Is Involved in Mesothelial-Mesenchymal Transition of Human Pleural Mesothelial Cells.
Tucker T; Tsukasaki Y; Sakai T; Mitsuhashi S; Komatsu S; Jeffers A; Idell S; Ikebe M
Am J Respir Cell Mol Biol; 2019 Jul; 61(1):86-96. PubMed ID: 30605348
[TBL] [Abstract][Full Text] [Related]
47. Role of molecular testing for malignant pleural effusion in targeted therapy for advanced non-small cell lung cancer.
Lin R; Li Y; Lin Y; Tian W; Jiang L; Li J
Diagn Cytopathol; 2023 Jul; 51(7):397-405. PubMed ID: 37078537
[TBL] [Abstract][Full Text] [Related]
48. Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma.
Jeong HO; Lee H; Kim H; Jang J; Kim S; Hwang T; Choi DW; Kim HS; Lee N; Lee YM; Park S; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee S; Lee SH
iScience; 2022 Nov; 25(11):105358. PubMed ID: 36339256
[TBL] [Abstract][Full Text] [Related]
49. Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma.
Son SM; Woo CG; Han HS; Lee KH; Lim YH; Lee OJ
Clin Chem Lab Med; 2020 Aug; 58(9):1547-1555. PubMed ID: 32229655
[TBL] [Abstract][Full Text] [Related]
50. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
[TBL] [Abstract][Full Text] [Related]
51. Culture and multiomic analysis of lung cancer patient-derived pleural effusions revealed distinct druggable molecular types.
Seo HY; Kim SC; Roh WL; Shin YK; Kim S; Kim DW; Kim TM; Ku JL
Sci Rep; 2022 Apr; 12(1):6345. PubMed ID: 35428753
[TBL] [Abstract][Full Text] [Related]
52. DOCK2 Promotes Pleural Fibrosis by Modulating Mesothelial to Mesenchymal Transition.
Qian G; Adeyanju O; Roy S; Sunil C; Jeffers A; Guo X; Ikebe M; Idell S; Tucker TA
Am J Respir Cell Mol Biol; 2022 Feb; 66(2):171-182. PubMed ID: 34710342
[TBL] [Abstract][Full Text] [Related]
53. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway.
Tsai MF; Chang TH; Wu SG; Yang HY; Hsu YC; Yang PC; Shih JY
Sci Rep; 2015 Sep; 5():13574. PubMed ID: 26338423
[TBL] [Abstract][Full Text] [Related]
54. Structural basis for hyperpermeability of tumor vessels in advanced lung adenocarcinoma complicated by pleural effusion.
Damianovich M; Hout Siloni G; Barshack I; Simansky DA; Kidron D; Dar E; Avivi C; Onn A
Clin Lung Cancer; 2013 Nov; 14(6):688-98. PubMed ID: 23931900
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion.
Nokihara H; Ogino H; Mitsuhashi A; Kondo K; Ogawa E; Ozaki R; Yabuki Y; Yoneda H; Otsuka K; Nishioka Y
BMC Cancer; 2022 Jun; 22(1):597. PubMed ID: 35650550
[TBL] [Abstract][Full Text] [Related]
56. TSAd Plays a Major Role in Myo9b-Mediated Suppression of Malignant Pleural Effusion by Regulating T
Yi FS; Zhang X; Zhai K; Huang ZY; Wu XZ; Wu MT; Shi XY; Pei XB; Dong SF; Wang W; Yang Y; Du J; Luo ZT; Shi HZ
J Immunol; 2020 Nov; 205(10):2926-2935. PubMed ID: 33046503
[TBL] [Abstract][Full Text] [Related]
57. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Hsu IL; Su WC; Yan JJ; Chang JM; Lai WW
Lung Cancer; 2009 Sep; 65(3):371-6. PubMed ID: 19157636
[TBL] [Abstract][Full Text] [Related]
58. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
[TBL] [Abstract][Full Text] [Related]
59. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.
Kasapoglu US; Arınç S; Gungor S; Irmak I; Guney P; Aksoy F; Bandak D; Hazar A
Clin Respir J; 2016 Nov; 10(6):791-799. PubMed ID: 25764010
[TBL] [Abstract][Full Text] [Related]
60. Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages.
Li L; Yang L; Wang L; Wang F; Zhang Z; Li J; Yue D; Chen X; Ping Y; Huang L; Zhang B; Zhang Y
Int J Cancer; 2016 Nov; 139(10):2261-9. PubMed ID: 27459735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
